콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

239631

Sigma-Aldrich

Acetylsalicylic acid

≥99%

동의어(들):

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

로그인조직 및 계약 가격 보기


About This Item

Linear Formula:
2-(CH3CO2)C6H4CO2H
CAS Number:
Molecular Weight:
180.16
Beilstein:
779271
EC Number:
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:

분석

≥99%

mp

134-136 °C (lit.)

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

유전자 정보

유사한 제품을 찾으십니까? 방문 제품 비교 안내

생화학적/생리학적 작용

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

픽토그램

Exclamation mark

신호어

Warning

유해 및 위험 성명서

예방조치 성명서

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point (°F)

482.0 °F

Flash Point (°C)

250 °C

개인 보호 장비

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Laurent Arnaud et al.
Autoimmunity reviews, 13(3), 281-291 (2013-11-06)
We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+). Observational and interventional studies identified from the Medline, Embase and Cochrane databases were selected if they

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.